Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Quanta Therapeutics
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Pathologically documented, locally advanced or metastatic malignancy with KRAS G12D mutations identified through molecular testing (NGS- or PCR-based) with a Clinical Laboratory Improvement Amendments-certified (or equivalent) diagnostic.
Part 1: Advanced solid tumors with at least one prior systemic therapy.
Evaluable and measurable disease per RECIST v1.1.
Part 2 and 3: Measurable disease per RECIST v1.1
You may not be if
Active brain metastasis or carcinomatous meningitis
Significant cardiovascular disease
Active infection requiring intravenous (IV) antibiotics
Prior treatment with a KRAS inhibitor
Clareo Health | QTX3046 in Patients With KRAS G12D Mutations
